Biochem/physiol Actions

Primary TargetP2X₇

General description

A potent, competitive, and selective antagonist of P2X₇ purinergic receptor (pIC₅₀ = 6.5 nM and 6.9 nM for rat and human P2X₇ receptor, respectively). Shown to reduce ATP-induced reactive oxygen species formation in MEL cells by about 87% (~10 µM) and blocks BzATP-stimulated changes in intracellular calcium concentrations (IC₅₀ = 100 and 300 nM at rat and human P2X₇ receptors, respectively.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Donnelly-Roberts, et al., 2007, Br. J. Pharmacol.101, 571.r>Wang B, et al., 2013, Purinergic Signal.9, 101.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)